Reports related to this article:
Project(s): View 4 related projects in PECWeb
Plant(s): View 4 related plants in PECWeb
Released January 17, 2014 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--It would be a hard to say just what the true health of the economy is today, with so many conflicting reports. With the general financial forecast still gyrating between growth and despair, it is gratifying to offer some positive news from the Pharmaceutical-Biotech Industry. According to a recent analysis of Industrial Info's Pharmaceutical Tracker - Online Database, a projected $20.8 billion in active reported projects are scheduled to begin construction in 2014, allocated among 720 active capital and maintenance, repair and operations (MRO) projects.
Click on the image at right for a graph detailing Pharmaceutical-Biotech Industry MRO projects that are set to begin in 2014 by activity phase.
A word of caution: It is important to remember that any reported project is up for debate, up to and including when it is under construction. Industrial Info will continue to monitor the project activity closely, making appropriate changes to both project status and value. From a dollar standpoint, the majority of reported projects for 2014 thus far fall into the early planning category ($11.4 billion), with the remainder a little further along in the development process.
Some may be put on hold until the financial markets and the industry itself continue to evolve and stabilize, and others will move up to take their places. Change is usually the only thing that can be assured. However, this industry and its three "Big D's"--Big Drama, Big Drugs and Big Dollars--offer the additional guarantee that the ride into its next incarnation will never be labeled as a boring journey in anyone's book.
Some of the bigger projects on the table for 2014 are from the public sector, including the $714 million National Bio and Agro-Defense Facility (NBAF). While funding for the nearly 600,000-square-foot research facility, slated for Manhattan, Kansas, is still being bandied about in Washington, the most recent news has it set to launch construction sometime this year. The national lab will replace the aging Plum Island Animal Disease Center (PIADC) in New York. Filled with elaborate laboratories ranging in biosafety levels (BSL) 1 through 4 (with the BSL-4 labs researching the most lethal of diseases and germs), the focus of study will center on integrated human, foreign animal and zoonotic diseases, as well as the development of large livestock vaccines. The project team includes designers Perkins + Will (Atlanta, Georgia), and a joint venture by McCarthy and Mortenson (McMjv) as construction managers.
Another public job is the planned launch of a $318 million project at Stony Brook University in Albany. AECOM (NYSE:ACM) (New York, New York) designed and will be project manager for the Medical & Research Translation Building (MART) & Bed Tower. Construction should begin later this year, with bids now on the street. It is on trend that a project that features a major research component is paired as one with a 150-bed patient wing. The goal of translational medicine is to get a treatment from "bench to bedside" as quickly as possible.
New York is also the location of a $250 million project on the Buffalo Niagara Medical Campus. The 200,000- to 300,000-square-foot Life Science Innovation Center 2 will house Albany Molecular Research Incorporated's (AMRI) (Albany, New York) 100,000-square-foot research facility, along with other multiple commercial life science operations. Krog Corporation (Orchard Park, New York) is on board, as other team members are put in place.
Bristol-Myers Squibb (NYSE:BMY) has tapped ARC/Architectural resources (Cambridge, Massachusetts) and Lend Lease (Lexington, Massachusetts) to handle construction of a $250 million expansion project in Devens, Massachusetts. Two buildings totaling 200,000 square feet will be added to the existing BMS large-scale, six-building, 400,000-square-foot biologics manufacturing campus in Devens. The expansion is to add both drug- and process-development capacity, as well as clinical-scale manufacturing.
View Plant Profile - 1069966 1068753 1059927 1068723
View Project Report - 33001345 300081565 300105937 300115243
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and nine international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
Click on the image at right for a graph detailing Pharmaceutical-Biotech Industry MRO projects that are set to begin in 2014 by activity phase. A word of caution: It is important to remember that any reported project is up for debate, up to and including when it is under construction. Industrial Info will continue to monitor the project activity closely, making appropriate changes to both project status and value. From a dollar standpoint, the majority of reported projects for 2014 thus far fall into the early planning category ($11.4 billion), with the remainder a little further along in the development process.
Some may be put on hold until the financial markets and the industry itself continue to evolve and stabilize, and others will move up to take their places. Change is usually the only thing that can be assured. However, this industry and its three "Big D's"--Big Drama, Big Drugs and Big Dollars--offer the additional guarantee that the ride into its next incarnation will never be labeled as a boring journey in anyone's book.
Some of the bigger projects on the table for 2014 are from the public sector, including the $714 million National Bio and Agro-Defense Facility (NBAF). While funding for the nearly 600,000-square-foot research facility, slated for Manhattan, Kansas, is still being bandied about in Washington, the most recent news has it set to launch construction sometime this year. The national lab will replace the aging Plum Island Animal Disease Center (PIADC) in New York. Filled with elaborate laboratories ranging in biosafety levels (BSL) 1 through 4 (with the BSL-4 labs researching the most lethal of diseases and germs), the focus of study will center on integrated human, foreign animal and zoonotic diseases, as well as the development of large livestock vaccines. The project team includes designers Perkins + Will (Atlanta, Georgia), and a joint venture by McCarthy and Mortenson (McMjv) as construction managers.
Another public job is the planned launch of a $318 million project at Stony Brook University in Albany. AECOM (NYSE:ACM) (New York, New York) designed and will be project manager for the Medical & Research Translation Building (MART) & Bed Tower. Construction should begin later this year, with bids now on the street. It is on trend that a project that features a major research component is paired as one with a 150-bed patient wing. The goal of translational medicine is to get a treatment from "bench to bedside" as quickly as possible.
New York is also the location of a $250 million project on the Buffalo Niagara Medical Campus. The 200,000- to 300,000-square-foot Life Science Innovation Center 2 will house Albany Molecular Research Incorporated's (AMRI) (Albany, New York) 100,000-square-foot research facility, along with other multiple commercial life science operations. Krog Corporation (Orchard Park, New York) is on board, as other team members are put in place.
Bristol-Myers Squibb (NYSE:BMY) has tapped ARC/Architectural resources (Cambridge, Massachusetts) and Lend Lease (Lexington, Massachusetts) to handle construction of a $250 million expansion project in Devens, Massachusetts. Two buildings totaling 200,000 square feet will be added to the existing BMS large-scale, six-building, 400,000-square-foot biologics manufacturing campus in Devens. The expansion is to add both drug- and process-development capacity, as well as clinical-scale manufacturing.
View Plant Profile - 1069966 1068753 1059927 1068723
View Project Report - 33001345 300081565 300105937 300115243
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and nine international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
